Published in Growth Horm IGF Res on January 12, 2007
Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study. Lancet (2006) 6.50
Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects. N Engl J Med (2010) 4.52
Digenic mutations account for variable phenotypes in idiopathic hypogonadotropic hypogonadism. J Clin Invest (2007) 3.20
The ectopic adrenocorticotropin syndrome: clinical features, diagnosis, management, and long-term follow-up. J Clin Endocrinol Metab (2005) 2.80
Cardiovascular responses to weight management and sibutramine in high-risk subjects: an analysis from the SCOUT trial. Eur Heart J (2007) 2.56
Endometrial safety and bleeding pattern during a five-year treatment with long-cycle hormone therapy. Menopause (2005) 2.03
123I-metaiodobenzylguanidine (MIBG) scintigraphy for the detection of adrenal and extra-adrenal phaeochromocytomas: CT and MRI correlation. Clin Endocrinol (Oxf) (2008) 1.78
Adrenal insufficiency in liver disease - what is the evidence? J Hepatol (2007) 1.69
Overall and cause-specific mortality in GH-deficient adults on GH replacement. Eur J Endocrinol (2012) 1.62
Mutations in fibroblast growth factor receptor 1 cause Kallmann syndrome with a wide spectrum of reproductive phenotypes. Mol Cell Endocrinol (2006) 1.62
The value of the low-dose dexamethasone suppression test in the differential diagnosis of hyperandrogenism in women. J Clin Endocrinol Metab (2003) 1.61
Discriminatory value of the low-dose dexamethasone suppression test in establishing the diagnosis and differential diagnosis of Cushing's syndrome. J Clin Endocrinol Metab (2003) 1.60
Management of obesity in adults: European clinical practice guidelines. Obes Facts (2008) 1.59
Growth hormone treatment in children is not associated with an increase in the incidence of cancer: experience from KIGS (Pfizer International Growth Database). J Pediatr (2010) 1.58
Unmasking of central hypothyroidism following growth hormone replacement in adult hypopituitary patients. Clin Endocrinol (Oxf) (2007) 1.50
Growth hormone dose-dependent pubertal growth: a randomized trial in short children with low growth hormone secretion. Horm Res Paediatr (2014) 1.47
Tamoxifen-induced anorexia is associated with fatty acid synthase inhibition in the ventromedial nucleus of the hypothalamus and accumulation of malonyl-CoA. Diabetes (2006) 1.46
The role of the aryl hydrocarbon receptor-interacting protein gene in familial and sporadic pituitary adenomas. J Clin Endocrinol Metab (2008) 1.42
Impact of the primary aetiology upon the clinical outcome of adults with childhood-onset GH deficiency. Eur J Endocrinol (2007) 1.42
Association of hypoglycemic treatment regimens with cardiovascular outcomes in overweight and obese subjects with type 2 diabetes: a substudy of the SCOUT trial. Diabetes Care (2013) 1.41
Application of the disease-specific Quality of Life Assessment of Growth Hormone Deficiency in Adults (QoL-AGHDA) questionnaire in a general population: results from a French panel study. Value Health (2010) 1.39
Joint statement of the European Association for the Study of Obesity and the European Society of Hypertension: obesity and difficult to treat arterial hypertension. J Hypertens (2012) 1.37
Validation of a quantitative magnetic resonance method for measuring human body composition. Obesity (Silver Spring) (2008) 1.34
Clinical manifestations of familial paraganglioma and phaeochromocytomas in succinate dehydrogenase B (SDH-B) gene mutation carriers. Clin Endocrinol (Oxf) (2008) 1.32
CT and MR imaging of unusual locations of extra-adrenal paragangliomas (pheochromocytomas). Eur Radiol (2004) 1.29
Annual screening detects celiac disease in children with type 1 diabetes. Pediatr Diabetes (2008) 1.26
Long-term safety of pegvisomant in patients with acromegaly: comprehensive review of 1288 subjects in ACROSTUDY. J Clin Endocrinol Metab (2012) 1.24
International trends of Down syndrome 1993-2004: Births in relation to maternal age and terminations of pregnancies. Birth Defects Res A Clin Mol Teratol (2010) 1.22
Dose-dependent effect of growth hormone on final height in children with short stature without growth hormone deficiency. J Clin Endocrinol Metab (2008) 1.11
The impact of glucocorticoid replacement regimens on metabolic outcome and comorbidity in hypopituitary patients. J Clin Endocrinol Metab (2006) 1.11
Contrasting clinical manifestations of SDHB and VHL associated chromaffin tumours. Endocr Relat Cancer (2009) 1.09
Clinical and biochemical characteristics of adrenocorticotropin-secreting macroadenomas. J Clin Endocrinol Metab (2005) 1.09
Kallmann syndrome: adhesion, afferents, and anosmia. Neuron (2002) 1.06
Cost-effectiveness analysis in glaucoma: what drives utility? Results from a pilot study in Sweden. Acta Ophthalmol Scand (2006) 1.05
Coding sequence analysis of GNRHR and GPR54 in patients with congenital and adult-onset forms of hypogonadotropic hypogonadism. Eur J Endocrinol (2006) 1.05
Feasibility and indicative results from a 12-month low-energy liquid diet treatment and maintenance programme for severe obesity. Br J Gen Pract (2013) 1.04
Determinants of cardiovascular risk in 2589 hypopituitary GH-deficient adults - a KIMS database analysis. Eur J Endocrinol (2006) 1.03
Modulation of glucocorticoid metabolism by the growth hormone - IGF-1 axis. Clin Endocrinol (Oxf) (2007) 1.02
Amelioration of sensory nerve dysfunction by C-Peptide in patients with type 1 diabetes. Diabetes (2003) 1.02
Levothyroxine treatment reduces thyroid size in children and adolescents with chronic autoimmune thyroiditis. J Clin Endocrinol Metab (2006) 1.01
Changes in mortality and causes of death in the Swedish Down syndrome population. Am J Med Genet A (2013) 1.01
Improvements in behaviour and self-esteem following growth hormone treatment in short prepubertal children. Horm Res Paediatr (2011) 1.00
High risk of sensorineural hearing loss in men born small for gestational age with and without obesity or height catch-up growth: a prospective longitudinal register study on birth size in 245,000 Swedish conscripts. J Clin Endocrinol Metab (2005) 0.97
Uric acid as a risk factor for cardiovascular disease and mortality in overweight/obese individuals. PLoS One (2013) 0.97
Acute effect of weight loss on levels of total bilirubin in obese, cardiovascular high-risk patients: an analysis from the lead-in period of the Sibutramine Cardiovascular Outcome trial. Metabolism (2009) 0.97
Adrenal insufficiency: review of clinical outcomes with current glucocorticoid replacement therapy. Clin Endocrinol (Oxf) (2014) 0.96
Early electrophysiological abnormalities and clinical neuropathy: a prospective study in patients with type 1 diabetes. Diabetes Care (2013) 0.96
The prevalence and characteristic features of cyclicity and variability in Cushing's disease. Eur J Endocrinol (2009) 0.95
Glucose homeostasis and safety in patients with acromegaly converted from long-acting octreotide to pegvisomant. J Clin Endocrinol Metab (2005) 0.94
Expression of phosphorylated p27(Kip1) protein and Jun activation domain-binding protein 1 in human pituitary tumors. J Clin Endocrinol Metab (2002) 0.94
Registries as a tool in evidence-based medicine: example of KIMS (Pfizer International Metabolic Database). Pharmacoepidemiol Drug Saf (2008) 0.94
A rapid method for analyzing serum pro-insulin-like growth factor-II in patients with non-islet cell tumor hypoglycemia. J Clin Endocrinol Metab (2005) 0.94
The clinical, metabolic and endocrine features and the quality of life in adults with childhood-onset craniopharyngioma compared with adult-onset craniopharyngioma. Eur J Endocrinol (2005) 0.92
Does long-term GH replacement therapy in hypopituitary adults with GH deficiency normalise quality of life? Eur J Endocrinol (2006) 0.92
Diagnosis and localisation of insulinoma: the value of modern magnetic resonance imaging in conjunction with calcium stimulation catheterisation. Eur J Endocrinol (2010) 0.92
Growth hormone deficiency and replacement in hypopituitary patients previously treated for acromegaly or Cushing's disease. Eur J Endocrinol (2002) 0.92
Leisure-time activity is an important determinant of long-term weight maintenance after weight loss in the Sibutramine Trial on Obesity Reduction and Maintenance (STORM trial). Am J Clin Nutr (2003) 0.92
Prepubertal Cushing's disease is more common in males, but there is no increase in severity at diagnosis. J Clin Endocrinol Metab (2004) 0.91
CT and MR imaging of the adrenal glands in ACTH-independent cushing syndrome. Radiographics (2004) 0.91
The comparative effects of bariatric surgery on weight and type 2 diabetes. Obes Surg (2007) 0.91
Discontinuation of growth hormone (GH) treatment during the transition phase is an important factor determining the phenotype of young adults with nonidiopathic childhood-onset GH deficiency. J Clin Endocrinol Metab (2010) 0.91
Maternal enterovirus infection during pregnancy as a risk factor in offspring diagnosed with type 1 diabetes between 15 and 30 years of age. Exp Diabetes Res (2008) 0.90
Isolated growth hormone (GH) deficiency in adult patients: baseline clinical characteristics and responses to GH replacement in comparison with hypopituitary patients. A sub-analysis of the KIMS database. Growth Horm IGF Res (2005) 0.90
Using EQ-5D to derive general population-based utilities for the quality of life assessment of growth hormone deficiency in adults (QoL-AGHDA). Value Health (2007) 0.90
Action on obesity: comprehensive care for all. Clin Med (2013) 0.88
Factors influencing cure by transsphenoidal selective adenomectomy in paediatric Cushing's disease. Eur J Endocrinol (2005) 0.87
A heart without hormones. Lancet (2012) 0.87
Low dose dehydroepiandrosterone affects behavior in hypopituitary androgen-deficient women: a placebo-controlled trial. J Clin Endocrinol Metab (2002) 0.87
Seeking the optimal target range for insulin-like growth factor I during the treatment of adult growth hormone disorders. J Clin Endocrinol Metab (2003) 0.87
A prospective evaluation of postural stimulation testing, computed tomography and adrenal vein sampling in the differential diagnosis of primary aldosteronism. Clin Endocrinol (Oxf) (2012) 0.87
Cardiovascular risk in patients with growth hormone deficiency: effects of growth hormone substitution. Endocr Pract (2007) 0.87
Long-term remission and recurrence rates in Cushing's disease: predictive factors in a single-centre study. Eur J Endocrinol (2013) 0.87
Diagnosing unilateral primary aldosteronism - comparison of a clinical prediction score, computed tomography and adrenal venous sampling. Clin Endocrinol (Oxf) (2013) 0.87
Healthcare utilization, quality of life and patient-reported outcomes during two years of GH replacement therapy in GH-deficient adults--comparison between Sweden, The Netherlands and Germany. Eur J Endocrinol (2006) 0.86
Adult GH deficiency throughout lifetime. Eur J Endocrinol (2009) 0.86
Do intact collagen fibers increase dentin bond strength? Swed Dent J (2002) 0.85
Engaging patients, clinicians and health funders in weight management: the Counterweight Programme. Fam Pract (2008) 0.85
ABC of obesity. Management: part II--drugs. BMJ (2006) 0.85
Changes in height, weight, and body mass index in children with craniopharyngioma after three years of growth hormone therapy: analysis of KIGS (Pfizer International Growth Database). J Clin Endocrinol Metab (2004) 0.84
Determinants of IGF-I status in a large cohort of growth hormone-deficient (GHD) subjects: the role of timing of onset of GHD. Clin Endocrinol (Oxf) (2003) 0.84
Serum insulin-like growth factor I (IGF-I), IGF-binding proteins 2 and 3, and the risk for development of malignancies in adults with growth hormone (GH) deficiency treated with GH: data from KIMS (Pfizer International Metabolic Database). J Clin Endocrinol Metab (2010) 0.84
Improvement in insulin sensitivity without concomitant changes in body composition and cardiovascular risk markers following fixed administration of a very low growth hormone (GH) dose in adults with severe GH deficiency. Clin Endocrinol (Oxf) (2005) 0.84
Prevalence of diabetes mellitus in 6050 hypopituitary patients with adult-onset GH deficiency before GH replacement: a KIMS analysis. Eur J Endocrinol (2013) 0.84
Dysfunctional SEMA3E signaling underlies gonadotropin-releasing hormone neuron deficiency in Kallmann syndrome. J Clin Invest (2015) 0.84
Efficacy and safety of CP-945,598, a selective cannabinoid CB1 receptor antagonist, on weight loss and maintenance. Obesity (Silver Spring) (2011) 0.83
Differential changes in serum uric acid concentrations in sibutramine promoted weight loss in diabetes: results from four weeks of the lead-in period of the SCOUT trial. Nutr Metab (Lond) (2009) 0.83